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No-reflow occurs occasionally during percutaneous coronary intervention (PCI)
in patients with acute myocardial infarction. Coronary no-reflow is defined as
inadequate myocardial perfusion of a given coronary segment without angio-
graphic evidence of mechanical vessel obstruction. No-reflow during primary PCI
results in increasing mortality and morbidity.1 Generally, the treatment of no-
reflow is based on pharmacotherapy. In this case, even in both maximal pharma-
cotherapy and applying intraaortic balloon pump (IABP), refractory no-reflow
was successfully treated with emergent percutaneous cardiopulmonary support
(PCPS) in primary coronary intervention.
A 51-year-old woman developed sudden chest pain and was brought to our
hospital by ambulance within 1 hour of initial onset of chest pain. At admission,
blood pressure was 64/48 mmHg, pulse rate was 45/minute, and limbs were cold
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Coronary no-reflow is defined as inadequate myocardial perfusion of a given
coronary segment without angiographic evidence of mechanical vessel obstruction.
No-reflow is visualized angiographically as a reduction in thrombolysis in myocar-
dial infarction (TIMI) flow grade and is typically accompanied by chest pain,
electrocardiographic changes with ST-segment shift and possible hemodynamic
compromise. No-reflow during primary percutaneous coronary intervention (PCI)
results in increasing mortality and morbidity. Therefore, treatment of noreflow is
associated with improved clinical outcomes. Generally, the treatment of no-reflow is
based on pharmacotherapy. In this case, despite maximal pharmacotherapy and
intraaortic balloon pump (IABP), refractory no-reflow accompanied with cardio-
genic shock was successfully treated with percutaneous cardiopulmonary support
(PCPS). 
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INTRODUCTION
CASE REPORT
and cyanotic. She was diagnosed hypertension and dia-
betes mellitus, however, did not take any medication. She
had suffered chest pain for 3 years, and her pain aggra-
vated 3 days ago. An electrocardiogram showed complete
atrioventricular (AV) block with significant ST-elevation
on lead II, III, and aVF and reciprocal ST depression
without Q wave on leads V1-3, I and aVL. After admini-
stration of 500 mg of aspirin, 600 mg of clopidogrel, and
100 IU/kg of heparin, the patient underwent primary
percutaneous coronary intervention. After temporary
pacemaker was inserted, the left coronary angiography
using the 5F Judkin left catheter revealed total occlusion in
the proximal left anterior descending (LAD) with throm-
bolysis in myocardial infarction (TIMI) grade 0 distal flow
(Fig. 1A). Right coronary angiography using 7F Judkin
right guiding catheter showed a total occlusion in the
proximal right coronary artery (RCA) with TIMI grade 0
distal flow (Fig. 1B). Thrombus aspiration using throm-
buster catheter (Kaneka Medix corporation, Osaka, Japan)
was performed, and a large amount of red thrombi were
aspi-rated and distal flow was improved with TIMI II flow.
Then, Coronary stents (Endeavor 4.0×30 mm-distal,
Endeavor 4.0×30 mm-proximal,) were inserted and
inflated up to 16 atms. Follow-up angiogram showed no-
reflow phenomenon with TIMI I flow and blood pressure
(BP) was dropped to 50/30 mmHg (Fig. 1C). Adenosine
30 ug and nicorandil 500 ug were injected repeatedly via
intracoronary route. Abciximab (ReoPro®, Lilly Pharma
Production GmbH & Co., Hamburg, Germany); 0.25
mg/kg IV bolus and 10 ug/min IV infusion were started
and IABP was applied. However, no-reflow was not
resolved, and hemodynamic instability was sustained (Fig.
1D). We decided to start 17 Fr femoral arterial sheath
(DLP®; Medtronic Inc., Minneapolis, MN, USA) and 21
Fr femoral long venous sheath (DLP®) through the right
femoral artery and vein (Fig. 1E). The PCPS was then
started using the Capiox emergency bypass system [emer-
gency bypass system (EBS); Terumo Inc, Tokyo, Japan],
which consists of a centrifugal pump, a polypropylene
hollow fiber membrane oxygenator, and a heparin-coated
circuit. The patient was transferred to the coronary care unit,
and hemodynamic status was stabilized 1 hour after starting
PCPS (BP 102/73 mmHg). Therefore, temporary pacema-
ker was removed due to resolved AV block. Emergent echo-
cardiography showed 14% ejection fraction, and her crea-
tinine kinase-MB fraction (CK-MB) rose to 1,316 mg/dL.
PCPS was continued for 2 days (33 hours). After 13 days,
follow up coronary angiography showed patent stent in
RCA and total occlusion in proximal LAD, which was
also treated with coronary stent (Endeavor 3.0×30 mm-
proximal) (Fig. 2A and B). After 15 days, the patient was
discharged. After 9 months of PCI, follow-up coronary
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Fig. 1. (A) Coronary angiography showed total occlusion in the proximal portions
(arrow) of left anterior descending. (B) Initial coronary angiography showed
total occlusion in mid portions (arrow) of right coronary artery with TIMI grade 0
distal flow. (C) Follow-up angiography immediately after stent implantation
showed no-reflow phenomenon at mid portion of RCA. (D) Catheterization
showed low arterial blood pressure in spite of  IABP  insertion. (E) Fluoroscopy
showed PCPS apply status. TIMI, thrombolysis in myocardial infarction; RCA,
right coronary artery; IABP, intraaortic balloon pump; PCPS, percutaneous
cardiopulmonary support.
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Fig. 2. (A) Follow-up angiography immediately after stent implantation at
proximal portion of LAD showed successful stent implantation (arrow). (B)
Follow-up angiography showed patent stents of RCA with TIMI grade III distal
flow after 13 days after stent implantation. (C) Follow up angiography at 9
months showed patent stent at LAD. (D) Follow up angiography at 9 months
showed patent stent at RCA. LAD, left anterior descending; RCA, right coronary
artery; TIMI, thrombolysis in myocardial infarction.
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angiography was performed due to dyspnea and chest tigh-
tness. However, but coronary stents at LAD and RCA were
patent (Fig. 2C and D), and follow-up echocardiography
showed 27% ejection fraction and increased left ventri-
cular end systolic/diastolic dimension (41/38 � 63/53 mm). 
To our best knowledge, this is the first report that refractory
no-reflow accompanied with cardiogenic shock, was
successfully treated with PCPS in the primary PCI setting,
despite maximal pharmacotherapy and IABP. The inci-
dence of no-reflow varies according to the subgroup of
patients studied, occurring in 2% to 5% of patients under-
going percutaneous coronary interventions.2 No-reflow is
visualized angiographically as a reduction in TIMI flow
grade and is typically accompanied by chest pain, electro-
cardiographic changes with ST-segment shift and possible
hemodynamic compromise. In a large study of primary
and rescue PCI,1  patients were stratified into three groups
(normal reflow, reversible no-reflow, and refractory no-
reflow), and 30-day mortalities were 3.7, 2.8 and 32.0% for
each group, respectively. Therefore, successful treatment
of refractory no-reflow is associated with improved clini-
cal outcomes. Treatment of no-reflow is based on pharma-
cotherapy. Various vasodilators and thrombolytic agents,
including verapamil, adenosine, nicorandil, nitroprusside
and abciximab, have been used to treat no-reflow pheno-
menon.3 However, verapamil and nitroprusside are limited
by hypotension and bradyarrhythmia. When refractory no-
reflow with hypotension is developed, the best manage-
ment is IABP and consideration of inotropes, because
IABP improves myocardial perfusion at the tissue level
and reduces the extent of no-reflow caused by microvas-
cular obstruction.4 If refractory hypotension persists des-
pite insertion of IABP, however, adjunctive treatment with
PCPS may be available to maintain the hemodynamics as a
conduit therapy. PCPS has an advantages of convenience
and the quick start up of hemodynamic support for the
vital organs during circulatory collapse, as short term
cardiac support.5 In the present patient, PCPS played an
important role in maintaining hemodynamic stability until
abciximab improved epicardial flow and microvascular
perfusion in patients with acute ST elevation myocardial
infarction (STEMI).6 Therefore, combined therapy of
PCPS and abciximab seems to be benefitial to refractory
no-reflow in cardiogenic shock, when there is no response
of maximal pharmacotherapy and insertion of IABP. 
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